Earnings call
Alembic Pharmaceuticals Q1 FY27 earnings call: Alembic Pharmaceuticals Limited expects to launch another 15-odd products for the rest of the year
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The transcript does not name its quarter. Q1 FY27 is worked out from the date it was filed.
The company expects to launch another 15-odd products for the rest of the year. Consolidated revenue grew 26% year-on-year in the quarter ended 30 th June 2026, supported by growth across all major businesses; India branded business grew 7%, International Generics grew 37% and the API business grew 33%. The company launched 7 products, filed 4 ANDA's and received 10 approvals during the quarter ended 30 th June 2026. The company had around INR1,600 crores of gross debt in June; debt was higher than the March numbers because additional receivables increased with higher sales, and the company expects this to unwind as it progresses.
The numbers management gave
Results
- Animal Health division delivered 24% growth in the quarter ended 30 th June 2026, while Gynecology, Gastrology and Ophthalmology continued to perform well.
Show source
Animal Health delivered a particularly strong quarter with 24% growth, while key therapies such as Gynecology, Gastrology and Ophthalmology continued to perform well.
- U.S. revenues grew 49% year-on-year in the quarter ended 30 th June 2026, supported by volume growth, new launches, especially Bosutinib, and improving utilization of manufacturing assets; growth was predominantly volume driven despite pricing pressure.
Show source
U.S. revenues grew 49% year-on-year, supported by volume growth, new launches, especially Bosutinib and improving utilization of our manufacturing assets.
- Revenue grew 26% year-on-year to INR2,150 crores in the quarter ended 30 th June 2026, reflecting broad-based growth across businesses and continued portfolio momentum; consolidated revenue grew 26% year-on-year, supported by growth across all major businesses; India branded business grew 7%, International Generics grew 37% and the API business grew 33%.
Show source
During the quarter, consolidated revenue grew by 26% year- on-year supported by growth across all our major businesses.
- Reported EBITDA grew 21% year-on-year to INR348 crores, with EBITDA margin at 16%, in the quarter ended 30 th June 2026.
Show source
Reported EBITDA grew at 21% year-on-year to INR348 crores with EBITDA margin at 16%.
- Profit before tax grew 17% year-on-year to INR223 crores in the quarter ended 30 th June 2026, reflecting underlying operating performance and better operating leverage.
Show source
Profit before tax grew at 17% year-on-year to INR223 crores, reflecting the strength of the underlying operating performance and better operating leverage across the business.
- Effective tax rate was about 22% in the quarter ended 30 th June 2026, compared with around 19% in the corresponding quarter previous year.
Show source
At PAT level, the quarter reflected a higher effective tax rate of about 22% compared with around 19% in the corresponding quarter previous year.
Show 16 more statements
Results
- Profit after tax grew 12% year-on-year to INR173 crores in the quarter ended 30 th June 2026 following its migration to the new tax regime.
Show source
As mentioned in our previous call, we migrated to the new tax regime and consequently, profit after tax grew at 12% year-on-year to INR173 crores, underlining the resilience of the business performance.
- U.S. business excluding Bosutinib grew closer to 25% in Q1, predominantly due to new launches.
Show source
I think ex of Bosutinib, also our business has grown over 20% in the US, closer to 25% that we've grown.
- Gross margins were within the guided 70% to 75% range, with solvent prices rising amid Middle East issues and product mix affecting gross margins.
Show source
And if you remember, we had a guidance of about 70% to 75% range for gross margins, and it sits well within that.
- Animal Health business was about 22% of India business revenue, and acute was about 37%.
Show source
So just to correct, Animal Health is about 22% of our overall revenue in the India business.
- Animal Health business continued to grow at about 20-plus percent, supported by expansion within its existing farm animals and poultry portfolio, field-force-driven volume and productivity improvements, and operational-efficiency measures.
Show source
So it’s the other way but yes, the underlying -- so there has been good growth in the animal health, we continue to grow at about 20-plus percent.
- U.S. business had about 49% year-on-year growth in rupee terms in the quarter ended 30 th June 2026; after taking out the currency impact of about 10% year-on-year, underlying constant currency growth was about 37% to 38%.
Show source
So the underlying constant currency growth is about 38 -- 37%, 38%.
- Specialty business was roughly 60% of its total revenue in quarter 1.
Show source
G. Krishnan: So see, the specialty business is roughly about close to about 60% of our total revenue.
- The company was very closely aligned to market growth in Gynae, Gastro and Ophthal therapies in quarter 1.
Show source
And when you look at the breakup of this, we are very closely aligned to the market growth on Gynae, Gastro and Ophthal therapies.
- The company is amortizing intangible assets acquired through the U.S. branded business product acquisition over an estimated 7 or 8 years; those assets were capitalized in quarter 4, contributing to higher year-on-year depreciation.
Show source
So that is getting amortized over the life of the asset, I think around 7 or 8 years is what we have considered.
- About 70% to 75% of Alembic Pharmaceuticals Limited's increase in depreciation would be due to intangibles.
Show source
But yes, so around 70%, 75% of that increase would be due to intangibles.
- Bosutinib had low volumes because its indication is small, while pricing was good; it had only one month of sales in the quarter after launching in June.
Show source
So you only have one month of sales.
- Gastroenterology, ophthalmics and cardio divisions are growing in double digits.
Show source
I think those are growing in double digits anyway.
- The company said its finance cost reflected a combination of increased debt and reduced interest rates.
Show source
So that's the net impact that we are seeing in the finance cost.
- Consolidated revenue grew 26% year-on-year in the quarter ended 30 th June 2026, supported by growth across all major businesses; India branded business grew 7%, International Generics grew 37% and the API business grew 33%. Replaced by a later filing.
Money and capital
- The company added about INR400 crores of capex in the last year.
Show source
And of course, we've added about INR400 crores of capex in the last year.
- The company had around INR1,600 crores of gross debt in June; debt was higher than the March numbers because additional receivables increased with higher sales, and the company expects this to unwind as it progresses.
Show source
So gross debt was about -- we are at around INR1,600 crores of gross debt and 2 things have happened.
What it expects ahead
What management expects
- The company expects to launch another 15-odd products for the rest of the year.
Show source
I think for the rest of the year, we should be launching another 15-odd products.
- The company expects its ex-U.S. business to grow about 15-odd percent in USD terms for the year, with some quarterly variation in supplies because it is mainly a B2B business.
Show source
I think about 15-odd percent or so of what I've guided for that the business will grow, and I think we're quite confident about that.
- The company expects its underlying core margins to improve from about 16% in FY26 to high-teens, partially offset by about 150 basis points of margin dilution from the US branded business; operating leverage on the core business was playing out in the first quarter and is expected to continue in the rest of the year through better utilization and volume-driven growth across US and ex-US markets.
Show source
And my comment was about the core margin improving to high-teens and which will partially get offset by the margin dilution from US branded business, which we said will be about 150 basis points, right?
- The company expects its API segment to grow around the 10% level for the year, above its guidance of about 10% plus/minus, and expects growth to continue in the next couple of quarters.
Show source
Moving forward, I think at the end of the year, we will be above that 10% level, around the 10% level that we had mentioned.
- The company expects its U.S. business to grow by about 10% to 15% this year excluding Bosutinib; growth will be higher because of Bosutinib and the momentum in new launches.
Show source
I think even ex- Bosutinib, as I mentioned, actually at the start of the year, I had mentioned that the US will grow by about 10% to 15%.
- The company expects a similar number of launches next year to the about 15 launches planned for the next 9 months of the year.
Show source
And even next year, we will see a similar number of launches.
Show 15 more statements
What management expects
- The company expects its U.S. business to grow mid to high teens in the year, subject to normal market conditions and continued execution, based on Q1 performance and trends, the launch outlook and current volume trends.
Show source
At the beginning of the year, we had indicated that the US Generics could grow in the low to mid-teens based on the performance and the trends we're seeing in Q1, the launch outlook and current volume trends, we now expect the US business to grow mid to high teens in the year, subject to normal market conditions and continued execution.
- Overall growth outlook for FY27 improved from the low double-digit range discussed earlier to closer to the mid-teen range.
Show source
As a result, we believe the overall growth outlook for the company can improve from the low double-digit range that we had discussed earlier to closer to the mid-teen range for FY27.
- The company expects its U.S. branded portfolio to start contributing positively next financial year onwards.
Show source
I expect that this will start contributing positively next financial year onwards.
- The company expects the drag caused by its U.S. branded business to gradually reduce quarter-on-quarter.
Show source
As we move forward quarter-on- quarter, we will gradually see a reduction in the drag that this business is causing us.
- The company expects U.S. branded business sales to pick up towards the end of the year and expects to reach breakeven as a trend by the end of this year, with positive contribution next year.
Show source
And that's why I'm saying that we should hopefully start getting to breakeven by the end of -- as a trend to the end of this year, and we'll see positive contribution next year.
- The company expects its EBITDA margin trajectory to reflect operating leverage in the core business excluding U.S. branded business, partially offset by the U.S. branded business, with operating margin maintained at an overall level as operating leverage plays out.
Show source
So we should see a similar trajectory of operating margin getting maintained at an overall level as we see operating leverage playing out.
- The company expects the recent trend to continue for the next quarter or two, while noting that price erosion and potential share loss could offset some of the momentum.
Show source
But at least for the next quarter or 2, I see that this trend should continue.
- Bosutinib exclusivity is in place until November, and the company expects some sales in Q2 and part of Q3; beyond that, competition could have a drastic effect because volumes are very small.
Show source
I know this exclusivity is there till November.
- The company expects it will take a couple of quarters to see the effects of Ramesh Juneja's work on its India Human Health business.
Show source
I think it will take a couple of quarters because it's a work in progress.
- The company expects to start seeing some positive trends in its India Human Health business in another quarter or two.
Show source
But I think we will start seeing some positive trends in another quarter or 2.
- The company expects to start seeing a positive trend in its India business in the next couple of quarters and aims to rectify the acute and other divisions that are dragging the business down.
Show source
And I think as I said earlier, to a question earlier that, we should start seeing some positive trend in the next couple of quarters.
- The company expects its India business to be close to market growth for the full year, with a few percentage points of variation.
Show source
So in terms of guidance for the full year, for the whole of India business, what we said is, we'll be aligned close to the market growth and maybe a few percentages here and there.
- The company expects new launches to continue and help offset price erosion in the U.S. business.
Show source
So I think the new launches will continue and that will help offset the erosion.
- The company expects operating leverage in its core business to play out, and expects the U.S. branded business to scale up in the next few quarters and contribute to profit, expanding the overall margin profile.
Show source
But directionally, I would like to say that the operating leverage will -- in the core business will play out.
- The company expects working capital to get optimized as the year progresses. Replaced by a later filing.
Show source
I think what we guided is at the beginning of the year that this working capital should get optimized as we progress.
What it is building and selling
Projects and capacity
- The company expanded capacity at the Ophthaline facility through preventive debottlenecking maintenance without incremental capex investment; a shutdown in the first quarter caused some cost under-absorption and diluted gross margins.
Show source
And that has now expanded the capacity without any incremental capex investment.
Demand and pricing
- The company has not seen another competitor in the Bosutinib market so far; an incumbent with the other strength may enter and the company may get the strength it does not have.
Show source
But as of now, I'm not seeing anybody else in the market so far.
- The company is seeing improving growth trajectory for Azithral and its acute portfolio around cough and cold.
Show source
Rahul, yes, we are seeing that trajectory improving, especially on Azithral and also in the overall portfolio of acute around cough and cold as well as we are seeing that traction building up.
Segments
- The company launched 7 products, filed 4 ANDA's and received 10 approvals during the quarter ended 30 th June 2026.
Show source
During the quarter, we launched 7 products, filed 4 ANDA's and received 10 approvals, further strengthening the launch platform for future growth.
- The company had about six to seven U.S. launches in Q1 and some in Q4.
Show source
We had about six to seven launches in Q1 and some in Q4.
- U.S. branded portfolio investment consists of field force and marketing expenses; the products come from a CMO and require no manufacturing or facility investment. Alembic Pharmaceuticals Limited's U.S. branded portfolio is a pure-play branding exercise, with expenses for marketing, branding and promotion.
Show source
And the expense that you see is only the marketing and branding and promotion costs.
Show 1 more statement
Segments
- U.S. branded portfolio is a pure-play branding exercise, with expenses for marketing, branding and promotion. Replaced by a later filing.
Risks, rules and outside factors
Outside factors
- The company says INR depreciation will help support pricing in the U.S. business.
Show source
G. Krishnan: But the way you should see the total reported growth because INR depreciation is going to help us in supporting the pricing.
Everything else said on the call
What management stressed
- The company wants to get its three US branded products off the ground before pursuing further opportunities.
Show source
But of course, right now, we want to take these 3 products and get them off the ground.
- The company says Ramesh Juneja joining expanded leadership bandwidth to focus more on execution.
Show source
Essentially, the point boils down to effective operational execution across these therapy areas. with Ramesh Juneja joining in, I think we have expanded the leadership bandwidth to focus more on the execution front.
- The company is seeking to drive growth through improving the quality of prescriptions from practitioners and increasing field productivity. Replaced by a later filing.
Show source
And the way we are looking at this in terms of driving the growth trajectory is a combination of 2, 3 aspects.
People and governance
- The company appointed Mr. Ramesh Juneja as Sales and Marketing Head for Human Health business.
Show source
With the appointment of Mr. Ramesh Juneja as Sales and Marketing Head for Human Health business, we have strengthened the execution leadership.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Damayanti Kerai: Okay. And apart from that, like any other meaningful launches which were added to US? Because your, I think, US run rate for launches have picked up in first quarter.
Answer, pranav amin
Pranav Amin: Yes. So let's take two parts of it, right? I think ex of Bosutinib, also our business has grown over 20% in the US, closer to 25% that we've grown. That is predominantly due to the new launches. As you know, with Alembic, what we do is we gradually pick up share. So new launches, when I say pick up share, is what we would have launched in Q4 as well as Q1. We had about six to seven launches in Q1 and some in Q4.
Answer, pranav amin
So I think both of those put together have also added a little more momentum to the US sales going forward.
Question
Damayanti Kerai: Okay. And as you revised up the outlook for US sales in FY25, we can assume new launch momentum should continue in the coming quarters as well?
Answer, pranav amin
Pranav Amin: Yes. I think for the rest of the year, we should be launching another 15-odd products.
Question
Damayanti Kerai: That's helpful. Then my second question is your investment towards the US branded portfolio where you have added another product. So what kind of investment you foresee for your efforts to really scale up this business? And you mentioned this will be eventually contributing positively to the profitability part. So in your initial experience with Pivya, what kind of time line we can assume when these products will start contributing positively to EBITDA? Like what could be the gestation period before we see benefits flowing in?
Answer, pranav amin
Pranav Amin: Yes. So as I mentioned, it's a soft launch. And the other two products are much smaller and we've just got into them. But Pivya also has been a soft launch. I think we will gradually start seeing a trend towards the second half of the -- towards the end of the year. I expect that this will start contributing positively next financial year onwards. As we move forward quarter-on- quarter, we will gradually see a reduction in the drag that this business is causing us.
Answer, pranav amin
And my goal is that next year onwards, we should start seeing a positive contribution.
Question
Damayanti Kerai: Okay. And in terms of investment, if you can call out any amount or where you have invested basically the SG&A team or you need to invest in building the marketing platforms, etcetera?
Answer, pranav amin
Pranav Amin: Yes. So in the investment is there's no hardware investment at all. The only investment that we have is the field force and the marketing expenses that we have. The product comes from a CMO. So there's no manufacturing, there's no facility. It's only a pure-play branding exercise. And the expense that you see is only the marketing and branding and promotion costs.
Question
Damayanti Kerai: Okay. So this cost would trend in line with how the top line picks up, right, and accordingly. Page 5 of 15 Alembic Pharmaceuticals Limited August 04, 2026 Pranav Amin: Yes.
Answer, pranav amin
So I think it will be the -- the revenue will scale up. It won't be linear, but it will be more like a J curve. So I think initially, we will have investments for the first quarter. I think we've seen one full quarter where we've been investing. Second quarter also, we'll invest. I think gradually, we'll see the sales pick up towards the end of the year. And that's why I'm saying that we should hopefully start getting to breakeven by the end of -- as a trend to the end of this year, and we'll see positive contribution next year.
Question
Damayanti Kerai: And my last question is, as you revised up your FY27 top line numbers, what -- how should we look at the EBITDA margin trajectory while we continue?
Answer, g krishnan
G. Krishnan: Yes. Thanks. So Damayanti, the EBITDA margin will broadly reflect the operating leverage that we have seen in the first quarter. And -- if I look at the underlying business ex-U.S. branded business, we have seen operating leverage playing out. And like we guided in the first Q4 results last year when we spoke in May, we said that there will be good operating leverage that will play out on the core business, which will partially get offset by the U.S. branded, and we hold on to that view at this point of time. So we should see a similar trajectory of operating margin getting maintained at an overall level as we see operating leverage playing out. And U.S. branded business, like Pranav mentioned, it should scale up as we progress in the subsequent quarters, which should bring back the margin -- build up the margin profile.
Question
Damayanti Kerai: Okay. Thank you. Thank you very much.
Answer, g krishnan
G. Krishnan: Yes, I'll take that. So yes, Q1 was the first full quarter of U.S. branded business launch. And we should see the margin profile get better from here. And for the full year, if I have to remind in the previous call, we guided about 150 basis points of dilution in the margin for the full year, and we hold on to that view at this point of time. And obviously, in the ramp-up phase, you will have the first few quarters of higher impact. And then as the sales picks up, it should moderate, the margin impact should moderate. So we still hold on to that view.
Answer, pranav amin
Pranav Amin: So Chirag, it's -- I would like it to be the new normal. But I think as you see, we have to balance that out with the erosion that we see and if we may lose some share. But I'm confident that the momentum that we have going forward, we should be able to continue some of it. Let's see how much price erosion we see for the next few quarters. But at least for the next quarter or 2, I see that this trend should continue. Chirag: Understood. Fair point.
Answer, pranav amin
Pranav Amin: No, I think -- so one thing about Bosutinib is the volumes of Bosutinib are quite small. It's because the indication is a small indication, while pricing is good. But we saw in the quarter only one month of sales. It was launched only in June. So you only have one month of sales. Chirag: Understood. And how are you thinking about sustainability of this revenue Pranav, going forward beyond the exclusivity period?
Answer, pranav amin
Pranav Amin: I think it's tough to say. I don't know that when they will -- because it's such a low-volume product, I don't -- I can't really foresee what's going to happen after a few months. I know this exclusivity is there till November. So you'll see Q2 and part of Q3, you will hopefully have some sales from Bosutinib. Over and above that, I think if there is competition, it will pretty much be -- it will be quite drastic because the volumes are very small. Chirag: But any sense on the competition, incremental competition that we see?
Answer, pranav amin
Pranav Amin: As of now, no, I haven't seen. I think the other incumbent who's got the other strength that may come in and we may get for the strength that we don't have. But I think that's what may happen. But as of now, I'm not seeing anybody else in the market so far. Chirag: For some time to come, this can be a 2-player market is how you're thinking about it?
Answer, g krishnan
G. Krishnan: So see, gross margins quarter-on-quarter was pretty much similar. And if you remember, we had a guidance of about 70% to 75% range for gross margins, and it sits well within that. And there have been a couple of factors which has influenced the gross margin. One is, of course, with a bit of the Middle East issues going on, we had seen solvent prices going up. That has had a bit of impact. And second is, of course, the product mix itself will -- has played a part. And third is we had taken a preventive debottlenecking maintenance upgrade in one of our facilities, especially the Ophthaline.
Answer, g krishnan
And that has now expanded the capacity without any incremental capex investment. And that shutdown was taken in the first quarter, which has resulted in a bit of under-absorption in the cost. So these are the 2, 3 factors that, where you would see the gross margins a bit diluted. But otherwise, it's still within the range that we have guided earlier, and we are comfortable with that. Chirag: Understood. Can I ask more questions? I have a few.
Answer, g krishnan
G. Krishnan: Yes, yes. So just to correct, Animal Health is about 22% of our overall revenue in the India business. And the acute is about 37% right. So it’s the other way but yes, the underlying -- so there has been good growth in the animal health, we continue to grow at about 20-plus percent. And we see that it's a combination of 2, 3 factors, again, expansion within the existing portfolio that we have got in the Animal Health, 'which is around farm animals and poultry, and we see that has continuing the momentum, along with the field force driving better volumes, better productivity, focus on operational efficiency measures that's continuing to help us build the momentum in Animal Health. Chirag: Understood. Yes, yes helpful.
Answer, pranav amin
Pranav Amin: So the ex-U.S. business has been a strong business for us, if you see over the last 5 years. And I think just maybe there may be some quarterly-to-quarterly variance because we are -- this is mainly a B2B business, right? And so there may be some quarterly-to-quarterly variance in terms of supplies. But at the end of the year, we stick to the guidance. I think about 15-odd percent or so of what I've guided for that the business will grow, and I think we're quite confident about that. Chirag: This is in USD terms, Pranav?
Question
Rahul Jeewani: Yes, sir. Thanks for taking my question. Sir, on the India business, you pointed to some management changes which you have implemented. So while on the Animal Health side, we continue to do well. When do you see our growth picking up on the human formulations business in India?
Answer, pranav amin
Pranav Amin: So, it's a good question, Rahul. I think, yes, 2 separate things. So the animal business we've left it as is, I think that is going on. On the human health side, we've got Ramesh Juneja, who's joined us recently and who is working at it. I think it will take a couple of quarters because it's a work in progress. I think we're going grassroots down to each territory, the nonperforming territories, what is happening with the new launches. So I think let's wait for a quarter or 2 to see start seeing.
Answer, pranav amin
But I think we will start seeing some positive trends in another quarter or 2.
Question
Rahul Jeewani: Sure, sir. And within the acute segment, have we started seeing some sort of growth pickup for our acute portfolio? And whatever happened with respect to Azithral during COVID, post- COVID, et cetera, is that largely in the base now as far as the acute segment is concerned?
Answer, g krishnan
G. Krishnan: Yes. Rahul, yes, we are seeing that trajectory improving, especially on Azithral and also in the overall portfolio of acute around cough and cold as well as we are seeing that traction building up. Page 9 of 15 Alembic Pharmaceuticals Limited August 04, 2026 Rahul Jeewani: Okay, sir.
Question
Sure. And coming back to margins for FY27, at one point in time, you indicated that the operating leverage on the base business would get offset by the investments on the US branded side. And at another point in call, you referred to high-teens margins as well. So I'm a bit confused in terms of what's margin guidance for FY27?
Answer, pranav amin
Pranav Amin: Sure. So see, the margin guidance is intact in the sense that let me reiterate the guidance again. So we did about 16% margins in FY26, and we believe that the margins -- the underlying core margins will improve. And my comment was about the core margin improving to high-teens and which will partially get offset by the margin dilution from US branded business, which we said will be about 150 basis points, right? So that remains intact. And we are seeing the operating leverage playing out in the first quarter as well on the core business, and which we believe will continue to happen in the rest of the year -- rest of the quarters as well as we see better utilization and good volume-driven growth across US and ex- US markets. Does that clarify, Rahul?
Show 12 more questions
Question
Rahul Jeewani: Sure, sir. So, versus FY26 levels would we stay largely flat on a full year basis. And if that is the case, then ideally this year, we are also benefiting from the exclusivity on Bosutinib, while the operating leverage on the base facilities was anyway is playing out. So are you talking about reported margins being flat in FY27? And if that is the case, then where, as I said, ideally Bosutinib should have helped us to significantly improve margins this year?
Answer, g krishnan
G. Krishnan: Yes. And we are also seeing the gross margins a bit diluted in the first half relative to the last year, right? So overall, the margin profile, you're right, in the sense that it should improve slightly better than the last year. But we are trying to see how the US branded business will play out in the rest of the quarters as we see the ramp-up, right? So it is about whether we're breaking even in quarter 4 or the next year first quarter, and it depends on where we land, whether it be better than the previous year or be flattish. It maybe a few percentage points here and there and a few quarters here or there.
Question
Rahul Jeewani: Sure, sir. And on the branded business, while we obviously are scaling up Pivya. Apart from Pivya also, are we looking at any other opportunities for the US branded portfolio?
Answer, pranav amin
Pranav Amin: Yes. So we are constantly searching for them. There's 2 other smaller ones, which we have already added. They also go with the same therapy in terms of doctors who are treating UTIs. So that is something that we're going to add. We just recently licensed, so that will also go along with that. Scouting for new opportunities as well.
Answer, pranav amin
But of course, right now, we want to take these 3 products and get them off the ground. Page 10 of 15 Alembic Pharmaceuticals Limited August 04, 2026 Rahul Jeewani: Sure, Pranav.
Question
Rashmi Shetty: Yes, thanks for the opportunity. Sir, what will be the outlook on the API segment?
Answer, pranav amin
Pranav Amin: Yes. So the API segment has been performing well for us. I think at the beginning of the year, we had given a guidance that it will grow about 10% plus/minus. Seeing the trend, I think Q1 has been quite healthy. Moving forward, I think at the end of the year, we will be above that 10% level, around the 10% level that we had mentioned. So I think we'll continue growing in the next couple of quarters as well.
Question
Rashmi Shetty: Okay. And in your India business, excluding the vet business, we are a bit underperforming the market. Like you mentioned that there were some changes in the management, and it will take some time to get back on track. So for full year, what will be the guidance on the specialty and the acute segment or as the whole domestic business piece, if you can explain that?
Answer, pranav amin
Pranav Amin: So let me just -- I'll just give a brief and then I'll get Krishnan on. I think so, in the India business, as we said, yes, animals is doing well. So let's keep that aside. In the Human Health side, we've got a new leader, Ramesh Juneja, who is heading the team now. But within that segment, if you see there are some which are still doing quite well. I think gastroenterology, ophthalmics and cardio that are doing well for us. I think those are growing in double digits anyway.
Answer, pranav amin
It's few of the acute and some of the other divisions which are dragging the business down. So I think our goal is to rectify that and see how we're going and get it up. And I think as I said earlier, to a question earlier that, we should start seeing some positive trend in the next couple of quarters. Krishnan, do you want to take it?
Answer, g krishnan
G. Krishnan: Yes. So in terms of guidance for the full year, for the whole of India business, what we said is, we'll be aligned close to the market growth and maybe a few percentages here and there. But directionally, we should be more aligned to the market growth.
Question
Rashmi Shetty: So you mean to say it should be in the low double-digit sort of growth this year?
Answer, g krishnan
G. Krishnan: So, it should be in the range of high single digit, but we will bridge the gap. Last year, the gap was much visible around the market growth versus what we had seen. And we believe that this year, we should be able to bridge the gap and be closely aligned to the market.
Question
Rashmi Shetty: Okay. And again, on this US business, while this year, what you call the contribution of the Bosutinib will be helping to deliver a higher growth. But in FY28, when the CGT will not be there and there will be a price erosion also in the existing portfolio, do you see that we'll still be Page 11 of 15 Alembic Pharmaceuticals Limited August 04, 2026 able to do a high single-digit growth led by any new launches? Or you feel that probably it would be more or less flattish over FY27?
Answer, pranav amin
Pranav Amin: So I think the main thing for the US business to grow, you have to have meaningful launches coming up. We believe we have a decent pipeline to continue with that. I think even ex- Bosutinib, as I mentioned, actually at the start of the year, I had mentioned that the US will grow by about 10% to 15%. We've just changed the guidance. It will go higher because of Bosutinib and the momentum we're seeing in the new launches. For the second half of the year, we are -- for the next 9 months of the year, we're seeing about 15 more launches that we will do. And even next year, we will see a similar number of launches.
Answer, pranav amin
So I think the new launches will continue and that will help offset the erosion. As regards to Bosutinib, yes, it's -- I don't see that opportunity over 6 months. But what will happen is, gradually, you will see the branded bit also starting to contribute next year onwards. So you will have the new launches as well as the branded business starting to contribute towards the growth going forward.
Question
Got it. Thank you.
Answer, g krishnan
G. Krishnan: So we had reported about 49% year-on-year growth in rupee terms. And roughly, you have seen about -- see, I think directionally, we don't intend to break up the INR depreciation part because that is going to support us on the pricing, right? So it is not right for us to break it down. But purely for the purpose of giving a number, you can take out the currency impact of about 10% year-on-year, right? So the underlying constant currency growth is about 38 -- 37%, 38%.
Question
Eshika Jain: 37%, 38%. Alright. Thank you.
Answer, g krishnan
G. Krishnan: But the way you should see the total reported growth because INR depreciation is going to help us in supporting the pricing.
Answer, g krishnan
G. Krishnan: So see, the specialty business is roughly about close to about 60% of our total revenue. I'm talking about quarter 1 numbers. And when you look at the breakup of this, we are very closely aligned to the market growth on Gynae, Gastro and Ophthal therapies. And the way we are looking at this in terms of driving the growth trajectory is a combination of 2, 3 aspects. First is about increasing the quality of prescriptions that we have got from the practitioners. And that is more about how you are driving the operational execution, focusing on the initiatives around expanding the -- consolidating the prescriber base and improving the quality of prescriptions. Second is increasing the field productivity, which is again an operating lever.
Answer, g krishnan
Essentially, the point boils down to effective operational execution across these therapy areas. with Ramesh Juneja joining in, I think we have expanded the leadership bandwidth to focus more on the execution front. Does that help.
Question
Foram Parekh: Yes, it does help. My second question is on the EBITDA margin again. So, we said that EBITDA margin in the core business has improved to high teens, but it's been diluted by 150 bps because of the marketing in the branded business. So, can we take like 18%, 19% kind of EBITDA margin for FY28 as this operational leverage in the branded business will play out? Page 13 of 15 Alembic Pharmaceuticals Limited August 04, 2026 G. Krishnan: FY28 is -- we will guide for FY28 when we get there.
Answer, g krishnan
But directionally, I would like to say that the operating leverage will -- in the core business will play out. And like Pranav mentioned, the US business -- US branded business is expected to scale up in the next few quarters. And that should contribute to profit. Today, it is diluting the margins, and it should start contributing to the profit, then it should as well expand the overall margin profile, right? Exact numbers, I think we will guide when we get there.
Question
Foram Parekh: Okay. And my third question is on the ROW side. So, we guided for 15% growth in INR terms. But historically, if we see, we have grown largely closer to 20% growth. So can we -- are we underguiding it or can we expect to surpass this 15% growth? Any outlook there?
Answer, pranav amin
Pranav Amin: Listen, so I think when we give a guidance, we have to give a guidance that we are 100% can achieve. So that's one thing. Number 2 is you have to understand that last year also was on a high base. So, let's see how this year goes.
Question
Foram Parekh: Thanks. Those were my questions.
Answer, g krishnan
G. Krishnan: Yes. So, depreciation is actually the intangible assets that we acquired because of -- driven by the US branded business expansion, the product acquisition that we did. So that is getting amortized over the life of the asset, I think around 7 or 8 years is what we have considered. So that's the depreciation year-on-year. It got capitalized in quarter 4, right? So, you would see the higher depreciation levels year-on-year. And of course, we've added about INR400 crores of capex in the last year.
Answer, g krishnan
G. Krishnan: Not fully. We have invested in capex, right? So that also will have an implication. But yes, so around 70%, 75% of that increase would be due to intangibles. Chirag: Understood. Thank you, sir.
Question
Rashmi Shetty: Thanks for the opportunity again. One question on the interest cost has also gone up compared to the previous quarter. So, if you can give us the gross debt figure as on June compared to the March level? And what is the outlook for the interest cost for the remaining part of the year? Page 14 of 15 Alembic Pharmaceuticals Limited August 04, 2026 G. Krishnan: Yes.
Answer, g krishnan
So gross debt was about -- we are at around INR1,600 crores of gross debt and 2 things have happened. So, one is we have the debt levels have a bit higher than the March numbers, it is purely towards additional receivables that has increased because of higher sales. So, it should unwind as we progress. And second is we have -- it's a combination of increase in debt, but reduction in interest rates. So that's the net impact that we are seeing in the finance cost. Yes, to your second question about where we will -- how this will progress during the rest of the year. I think what we guided is at the beginning of the year that this working capital should get optimized as we progress.
Questions about this call
- When was the Alembic Pharmaceuticals Q1 FY27 earnings call transcript filed?
- Alembic Pharmaceuticals filed the transcript with the exchange on 10 Aug 2026. This page is built from that transcript.
- What does this page list?
- 55 statements from the transcript across 9 topics, 25 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 22 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.